Regeneron Pharmaceutical (REGN) 378.35 $REGN
Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
PR Newswire - Fri Jul 08, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2016 financial and operating results on Thursday, August 4, 2016, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 378.35 (+6.90)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.64 (+0.26), PFE: 36.12 (+0.35), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Look for Shares of Regeneron Pharmaceuticals to Potentially Pullback after Yesterday's 2.49% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $355.61 to a high of $369.70. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $363.18 on volume of 477,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 378.35 (+6.90)
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
PR Newswire - Tue Jul 05, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
SAN: 3.90 (+0.17), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 2.44% Yesterday
Comtex SmarTrend(R) - Fri Jul 01, 12:37PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $348.43 to a high of $359.89. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $351.20 on volume of 433,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 378.35 (+6.90)
Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Pfizer's (PFE) bococizumab met the primary endpoints in two phase III studies in patients at high and very high risk for cardiovascular events.
PFE: 36.12 (+0.35), AMGN: 161.10 (+4.51), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
After Yesterday's Decline of 1.73%, Regeneron Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 1:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $329.09 to a high of $341.74. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $338.69 on volume of 652,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
Company News for June 23, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:10AM CDT
Companies in the News are: TSLA,SCTY,FDX,ADBE,REGN
FDX: 156.22 (+3.62), TSLA: 216.78 (+0.84), SCTY: 23.80 (-0.74), REGN: 378.35 (+6.90), ADBE: 96.79 (+1.65)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 88.96 (-1.09), XON: 26.72 (+0.83), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90)
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharmaceuticals After 1.02% Loss
Comtex SmarTrend(R) - Mon Jun 13, 12:43PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $367.45 to a high of $375.38. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $369.60 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 251.30 (+4.03), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), AMGN: 161.10 (+4.51), ABBV: 64.16 (+0.73), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Regeneron Pharmaceuticals Falls 1.47% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 08, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.98 to a high of $394.80. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $393.21 on volume of 473,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), PXD: 153.72 (+4.49), ALXN: 124.42 (+1.08), HAL: 45.03 (+1.48), EOG: 82.54 (+0.93), AMGN: 161.10 (+4.51), ILMN: 141.25 (+1.19), XOM: 93.54 (+0.58), COP: 42.30 (+0.79), JUNO: 27.81 (-13.01), CVX: 104.77 (+1.72), OXY: 76.13 (+0.68), REGN: 378.35 (+6.90)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 56.51 (-1.61), BMY: 75.28 (+1.20), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 3.90 (+0.17), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Regeneron Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:25PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
REGN: 378.35 (+6.90)
Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
PR Newswire - Fri Jul 08, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2016 financial and operating results on Thursday, August 4, 2016, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 378.35 (+6.90)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.64 (+0.26), PFE: 36.12 (+0.35), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Look for Shares of Regeneron Pharmaceuticals to Potentially Pullback after Yesterday's 2.49% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $355.61 to a high of $369.70. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $363.18 on volume of 477,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 378.35 (+6.90)
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
PR Newswire - Tue Jul 05, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
SAN: 3.90 (+0.17), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 2.44% Yesterday
Comtex SmarTrend(R) - Fri Jul 01, 12:37PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $348.43 to a high of $359.89. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $351.20 on volume of 433,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 378.35 (+6.90)
Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:09AM CDT
Pfizer's (PFE) bococizumab met the primary endpoints in two phase III studies in patients at high and very high risk for cardiovascular events.
PFE: 36.12 (+0.35), AMGN: 161.10 (+4.51), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
After Yesterday's Decline of 1.73%, Regeneron Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 1:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $329.09 to a high of $341.74. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $338.69 on volume of 652,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
Company News for June 23, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:10AM CDT
Companies in the News are: TSLA,SCTY,FDX,ADBE,REGN
FDX: 156.22 (+3.62), TSLA: 216.78 (+0.84), SCTY: 23.80 (-0.74), REGN: 378.35 (+6.90), ADBE: 96.79 (+1.65)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 88.96 (-1.09), XON: 26.72 (+0.83), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90)
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharmaceuticals After 1.02% Loss
Comtex SmarTrend(R) - Mon Jun 13, 12:43PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $367.45 to a high of $375.38. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $369.60 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 251.30 (+4.03), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), AMGN: 161.10 (+4.51), ABBV: 64.16 (+0.73), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Regeneron Pharmaceuticals Falls 1.47% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 08, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.98 to a high of $394.80. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $393.21 on volume of 473,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 378.35 (+6.90)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), PXD: 153.72 (+4.49), ALXN: 124.42 (+1.08), HAL: 45.03 (+1.48), EOG: 82.54 (+0.93), AMGN: 161.10 (+4.51), ILMN: 141.25 (+1.19), XOM: 93.54 (+0.58), COP: 42.30 (+0.79), JUNO: 27.81 (-13.01), CVX: 104.77 (+1.72), OXY: 76.13 (+0.68), REGN: 378.35 (+6.90)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 56.51 (-1.61), BMY: 75.28 (+1.20), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 3.90 (+0.17), SNY: 40.85 (-0.14), REGN: 378.35 (+6.90)
Regeneron Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:25PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
REGN: 378.35 (+6.90)
